Abstract
A number of monocyclic SFTI-1 analogues modified in the conserved inhibitor P1 position by Pro, its L-hydroxyproline (Hyp) derivative as well as mimetics with different ring size were synthesized by the solid-phase method. Replacement of Ser6 by Pro, Hyp, and a four-member ring, L-azetidine-2-carboxylic acid (Aze), retained trypsin or chymotrypsin inhibitory activity. The determined association equilibrium constants of these analogues with a cognate enzyme were about two orders of magnitude lower than those obtained for ones with conserved Ser6. In all analogues, with the exception of one, [Phe5,Aze6]SFTI-1, the P1-P1 reactive site remained intact. The results provide first evidence that the conserved Ser in the P1 position of Bowman-Birk inhibitors can be successfully replaced by an amino acid with a secondary amine group.
Keywords: Peptides, proteinase inhibitors, SFTI-1, mimetics of Pro, BB, BBI, Fmoc, DCM, DMF/NMP, NPGB, MALDI MS, BAPNA, HPLC, Proteolytic susceptibilityPeptides, proteinase inhibitors, SFTI-1, mimetics of Pro, BB, BBI, Fmoc, DCM, DMF/NMP, NPGB, MALDI MS, BAPNA, HPLC, Proteolytic susceptibility
Protein & Peptide Letters
Title: Introduction of Pro and Its Analogues in the Conserved P1 Position of Trypsin Inhibitor SFTI-1 Retains Its Inhibitory Activity
Volume: 18 Issue: 11
Author(s): Anna Legowska, Dawid Debowski, Rafal Lukajtis, Emilia Sztabkowska, Aneta Mizeria, Krzysztof Brzozowski, Magdalena Wysocka, Adam Lesner and Krzysztof Rolka
Affiliation:
Keywords: Peptides, proteinase inhibitors, SFTI-1, mimetics of Pro, BB, BBI, Fmoc, DCM, DMF/NMP, NPGB, MALDI MS, BAPNA, HPLC, Proteolytic susceptibilityPeptides, proteinase inhibitors, SFTI-1, mimetics of Pro, BB, BBI, Fmoc, DCM, DMF/NMP, NPGB, MALDI MS, BAPNA, HPLC, Proteolytic susceptibility
Abstract: A number of monocyclic SFTI-1 analogues modified in the conserved inhibitor P1 position by Pro, its L-hydroxyproline (Hyp) derivative as well as mimetics with different ring size were synthesized by the solid-phase method. Replacement of Ser6 by Pro, Hyp, and a four-member ring, L-azetidine-2-carboxylic acid (Aze), retained trypsin or chymotrypsin inhibitory activity. The determined association equilibrium constants of these analogues with a cognate enzyme were about two orders of magnitude lower than those obtained for ones with conserved Ser6. In all analogues, with the exception of one, [Phe5,Aze6]SFTI-1, the P1-P1 reactive site remained intact. The results provide first evidence that the conserved Ser in the P1 position of Bowman-Birk inhibitors can be successfully replaced by an amino acid with a secondary amine group.
Export Options
About this article
Cite this article as:
Legowska Anna, Debowski Dawid, Lukajtis Rafal, Sztabkowska Emilia, Mizeria Aneta, Brzozowski Krzysztof, Wysocka Magdalena, Lesner Adam and Rolka Krzysztof, Introduction of Pro and Its Analogues in the Conserved P1 Position of Trypsin Inhibitor SFTI-1 Retains Its Inhibitory Activity, Protein & Peptide Letters 2011; 18 (11) . https://dx.doi.org/10.2174/092986611797201002
DOI https://dx.doi.org/10.2174/092986611797201002 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Pleiotropic Beneficial Effects of Epigallocatechin Gallate, Quercetin and Delphinidin on Cardiovascular Diseases Associated with Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
Current Drug Targets New Technologies for Drug Delivery Across the Blood Brain Barrier
Current Pharmaceutical Design Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies ApoB-100 and HSP60 Peptides Exert a Synergetic Role in Inhibiting Early Atherosclerosis in Immunized ApoE-null Mice
Protein & Peptide Letters Ecological Infectomics (Ecoinfectomics): Symbiotic Solutions to Microbial Infections
Anti-Infective Agents The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Interferon Alpha2 in the Treatment of Hematological Malignancies. Status and Perspectives (Guest Editor: Hans Carl Hasselbalch)]
Current Drug Targets Recent Advances in Gut Nutrient Chemosensing
Current Medicinal Chemistry Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Current Medicinal Chemistry Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Current Topics in Medicinal Chemistry Adrenal Insufficiency in Sepsis
Current Pharmaceutical Design Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued)